Shantou Institute of Ultrasonic Instrument
301602
Hubei Sinophorus Electronic Materials
688545
Pansoft
300996
4
Jiayu Holding
300117
5
Wuxi Taclink Optoelectronics Technology
688205
US Stock MarketDetailed Quotes
SGMT Sagimet Biosciences
- 4.130
- -0.260-5.92%
Close Jan 21 16:00 ET
- 4.260
- +0.130+3.15%
Post 20:01 ET
132.97MMarket Cap-3.55P/E (TTM)
4.550High4.070Low1.10MVolume4.500Open4.390Pre Close4.62MTurnover6.19%Turnover RatioLossP/E (Static)32.20MShares11.76052wk High0.78P/B73.65MFloat Cap2.39052wk Low--Dividend TTM17.83MShs Float20.710Historical High--Div YieldTTM10.93%Amplitude2.130Historical Low4.184Avg Price1Lot Size
Trending Stocks
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Stocks & Industries to Watch Under Trump's Second Presidency
Key takeaways Tech stocks underwent substantial growth due to tax cuts and reduced corporate regulations in Trump's first term along with defense and aerospace
Discussing
Trump's return, earnings ahead: Can Tesla continue to climb?
🎙️Discussion: 1. With Trump's return, can Tesla's stock price continue to rise in 2025? 2. Tesla is set to release its earnings report aft
BullnBearTrading
Jan 3 16:30
🚗 Tesla Q4 Dip: Time to Buy , or Is the Risk Too High? 📉
Sagimet Biosciences Stock Forum
📊⚡️📊
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024
Sagimet Biosciences presented Phase 2b data for denifanstat, its fatty acid synthase (FASN) inhibitor, at AASLD 2024. The FASCINATE-2 trial showed significant improvement in liver fibrosis in high-risk MASH patients, particularly in the F3 population where 49% of denifanstat-treated patients showed improvement versus 13% for placebo. AI-ba...
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
Ascletis Pharma has completed enrollment of 480 patients in its Phase III clinical trial of ASC40 (denifanstat), a once-daily oral tablet for treating moderate to severe acne. The randomized, double-blind, placebo-controlled trial began on January 24, 2024, with patients divided equally between treatment and placebo groups. The study will evalua...
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions With FDA on the Development of Denifanstat for Mash; Phase 3 Program Initiation Expected by End of 2024
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
Sagimet Biosciences Inc. (Nasdaq: SGMT) announced the publication of results from their Phase 2b FASCINATE-2 clinical trial of denifanstat in The Lancet Gastroenterology & Hepatology. The trial, conducted on patients with biopsy-confirmed metabolic-dysfunction associated steatohep...
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in Mash
Sagimet Biosciences Inc. (Nasdaq: SCMT)
announced that the FDA has granted Breakthrough Therapy designation to denifanstat for treating noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.
This designation was supported by positive data from the Phase 2b FASCINATE-2 trial, where denifanstat showed statistically significant imp...
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in Mash
No comment yet